Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000344956

Medchemexpress LLC Lenvatinib (mesylate) | 857890-39-2 | 99.7% | 522.96 | 1 G
SDP

Catalog No. 5000344956
Encompass_Preferred

Lenvatinib mesylate is an oral, multi-targeted tyrosine kinase inhibitor that potently inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, demonstrating potent antitumor activities. It is intended for research use only.

  • Potent inhibition of multiple tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET.
  • Demonstrates potent antitumor activities.
  • Inhibits local tumor growth and metastasis in vivo.
  • Decreases microvessel density in xenograft models.

Catalog No. 50-003-44956 Supplier Medchemexpress LLC Supplier No. HY10981A10MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Lenvatinib mesylate is an oral, multi-targeted tyrosine kinase inhibitor that potently inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, demonstrating potent antitumor activities. It is intended for research use only.

  • Potent inhibition of multiple tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET.
  • Demonstrates potent antitumor activities.
  • Inhibits local tumor growth and metastasis in vivo.
  • Decreases microvessel density in xenograft models.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.